Oxaliplatin is a platinum-based antineoplastic chemotherapy drug used mainly for colorectal cancer, often in combination regimens such as FOLFOX or CAPOX. It is administered intravenously and marketed under the trade name Eloxatin. European approval occurred in 1996 and U.S. FDA approval followed in 2002.
A Phase 1b/2 trial in 28 patients found nivolumab plus modified FOLFIRINOX was well tolerated before surgery in borderline-resectable pancreatic cancer. Seventy-nine percent proceeded to surgery, with complete tumor removal in all resected patients.
A computational histology artificial intelligence platform can predict which of two chemotherapy regimens is more effective for individual pancreatic cancer patients, according to a study published in the Journal of Clinical Oncology.
Alphamab Oncology dosed the first patient in its Phase III trial of JSKN003, a biparatopic HER2-targeting antibody-drug conjugate, for HER2-positive advanced colorectal cancer on February 14, 2026.
Alphamab Oncology has dosed the first patient in a Phase III study of JSKN003, a biparatopic HER2-targeting ADC, for HER2-positive advanced colorectal cancer. The drug demonstrated a 68.8% response rate in earlier trials.
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT07613905 |
A Prospective Study on the Clinical Value of Skin Test for Oxaliplatin Hypersensitivity Reaction and Its Correlation With Biomarkers |
NOT_YET_RECRUITING | NA |
| NCT07606599 |
A Study of BL-M07D1 Versus Physician's Choice of Chemotherapy in Patients With HER2-expressing Locally Advanced or Metastatic Biliary Tract Cancer After Platinum-containing Chemotherapy Failure |
NOT_YET_RECRUITING | PHASE3 |
| NCT07599423 |
A Study of Glofitamab Plus GemOx Compared With Standard of Care in Patients With Relapsed/Refractory Large B-Cell Lymphoma |
NOT_YET_RECRUITING | PHASE2 |
| NCT07582315 |
A Study Comparing BL-B01D1 With Treatment of Physician's Choice in Patients With Locally Advanced or Metastatic Biliary Tract Cancer After Failure of Platinum-based Chemotherapy and PD-1/PD-L1 Monoclonal Antibody Therapy(PANKU-BTC01) |
NOT_YET_RECRUITING | PHASE3 |
| NCT07580339 |
Combining DCSZ11 With Radiation and Chemotherapy as Neoadjuvant Treatment for pMMR Locally Advanced Rectal Cancer |
NOT_YET_RECRUITING | PHASE2 |
| NCT07570914 |
Hepatic Arterial Infusion of Liposomal Irinotecan Plus Oxaliplatin and Capecitabine as Adjuvant Therapy for Colorectal Cancer Liver Metastases |
NOT_YET_RECRUITING | PHASE2 |
| NCT07570823 |
A Study to Evaluate the Safety and Efficacy of SCTB35 in Combination With Gemcitabine and Oxaliplatin in Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma |
NOT_YET_RECRUITING | PHASE3 |
| NCT07561060 |
Low Rectal Cancer Treated With Total Neoadjuvant Therapy Plus Concurrent Tislelizumab Immunotherapy |
RECRUITING | PHASE1/PHASE2 |
| NCT07554521 |
A Study to Evaluate Efficacy and Safety of Tislelizumab Plus Chemotherapy for Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Adenocarcinoma and Esophageal Squamous Cell Carcinoma in Racial and Ethnic Minority Patients in the United States |
RECRUITING | PHASE2 |
| NCT07554482 |
Selinexor Combined With Reduced-Dose Radiotherapy For Early-Stage Extranodal NK/T-Cell Lymphoma |
NOT_YET_RECRUITING | PHASE2 |
